Abstract
The occurrence of chronic skin inflammatory diseases, such as psoriasis and atopic dermatitis, has been increasing. However, currently available medicines are not sufficient to treat skin inflammatory diseases, so the development of effective medicines without the side effects has been demanded. Oxidative stress by accumulated reactive oxygen species induces and/or promotes inflammatory reactions. Therefore, many anti-oxidant molecules have been reported to have anti-inflammatory effects. Extracellular superoxide dismutase (SOD3) is an endogenous anti-oxidant enzyme that dismutates superoxide radicals into oxygen or hydrogen peroxide molecules in the extracellular space. A series of reports has suggested that exogenous recombinant SOD3 represses inflammatory responses not only by directly reducing reactive oxygen species but also by inhibiting cellular signaling pathways. Here, we demonstrate the potential of SOD3 as a novel biomedicine for treating inflammatory skin diseases and review preparations of active recombinant human SOD3 for clinical applications.
Financial & competing interests disclosure
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST; 20110002223). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Key issues
• Most inflammatory responses come along with increased amount of reactive oxygen species.
• An extracellular antioxidant enzyme, extracellular superoxide dismutase (SOD3) efficiently reduced inflammatory responses such as immune cell infiltration and expression and secretion of proinflammatory cytokines.
• Recombinant SOD3 has potential as a novel biomedicine treating inflammatory diseases, including chronic inflammatory skin diseases, such as psoriasis and atopic dermatitis.
• It is necessary to obtain large quantity of active SOD3 for clinical applications against inflammatory diseases.